ClinicalTrials.gg
RecruitingNCT07413939BREnnAUpdated Nov 5, 2026

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

A Phase 2/3 interventional study of RO7771950 and Tucatinib in HER2-positive Breast Cancer, sponsored by Hoffmann-La Roche. Recruiting at 219 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Hoffmann-La Roche · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 5, 2026First site in Ukraine33 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 229 studies in Breast Neoplasms by Hoffmann-La Roche — 16 open to participants now, 28 under way, 13 of them phase 3. Breast Neoplasms · Hoffmann-La Roche.

Planned enrollment
24th of 170
650 · median 151
Started
2026
with 9 others
Phase 2/3
2 of 229
1 open now
Primary completion
2029-05
later than 21 of 27 live
Registered
223rd of 229
by date

Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 24th largest by planned enrollment of the 170 interventional ones that give a count, is one of 10 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 21 of the 27 other live ones, and was the 223rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 229 studies in Breast Neoplasms by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 229 studies in Breast Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented locally advanced inoperable (LAI) or breast cancer (MBC) with confirmed -positive status by central laboratory.
  • as per by v1.1 in stage 1. Non-measurable disease allowed in stage 2.
  • Previously treated (stable or progressive) or previously untreated , or .
  • At least one prior line of anti-HER2-based therapy for LAI or metastatic disease.
  • Prior anti-HER2 antibody-drug conjugate (ADC), such as trastuzumab-deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1), in any treatment setting. Participants without prior ADC therapy may only be enrolled if approved standard-of-care (SOC) anti-HER2 ADC is not locally accessible at screening, or if there is a prospectively documented clinical .
  • Prior tyrosine kinase inhibitor (TKI) in the (neo) setting provided completion is > 12 months ahead of LAI occurrence. Prior treatment with TKIs for LAI/MBC is not permitted.
  • Has protocol-defined adequate organ and bone marrow function.
  • (ECOG) performance status 0 or 1.
  • Baseline (LVEF) ≥ 50%.

Exclusion criteria

Exclusion Criteria:

  • Concurrent anti-cancer treatment, or treatment with therapy within 28 days prior to initiation of study treatment.
  • Known active/untreated or C or chronic liver disease.
  • cardiovascular disease or risk, including heart failure ( (NYHA) ≥ II), ischemic heart disease or recent coronary events/interventions, clinically significant arrhythmias or (ECG) abnormalities, or risk of ventricular dysrhythmias, poorly controlled hypertension, peripheral arterial disease, dilated cardiomyopathy, or unstable angina.
  • Clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome.
  • Concomitant use of any drug or herbal medicine known to strongly inhibit or induce or CYP2C8 activity, oral coumarin-derivative anticoagulants.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
650 participants (estimated)

Study arms

  • Experimental
    Arm A - RO7771950 Dose Type 1

    Drug: RO7771950 · Drug: Trastuzumab · Drug: Capecitabine

  • Experimental
    Arm B - RO7771950 Dose Type 2

    Drug: RO7771950 · Drug: Trastuzumab · Drug: Capecitabine

  • Active comparator
    Arm C - Tucatinib

    Drug: Tucatinib · Drug: Trastuzumab · Drug: Capecitabine

Interventions

  • Participants will receive one of two doses of RO7771950 orally (PO) twice a day (BID).

    Also known as: ZN-A-1041, RG6596

  • Participants will receive a dose of tucatinib PO BID.

  • Participants will receive trastuzumab in accordance with local prescribing information, either through intravenous (IV) or subcutaneously (SC).

  • Participants will receive capecitabine according to local prescribing information. Capecitabine will be administered PO BID.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as Determined by Blinded Independent Central Review (BICR)

    Time from randomization to disease progression or death, according to standard criteria (Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)).

    Time frame: Approximately 35 months

Secondary outcomes

  1. Progression-free Survival in Participants with Central Nervous System Metastases (PFS-CNS) by BICR

    Time from randomization to disease progression or death, according to standard criteria (RECIST v1.1).

    Time frame: Approximately 35 months

  2. Overall Survival in Full Analysis Set (OS-FAS)

    Time from randomization to death from any cause.

    Time frame: Approximately 53 months

  3. Objective Response Rate (ORR) by BICR

    Proportion of participants with a complete response (CR), partial response (PR) according to standard criteria (RECIST v1.1).

    Time frame: Approximately 35 months

  4. Duration of Response (DOR) as per BICR

    Time from the first occurrence of an objective response (CR or PR) to disease progression or death from any cause according to standard criteria (RECIST v1.1).

    Time frame: Approximately 35 months

  5. Clinical Benefit Rate (CBR) as per BICR

    Proportion of participants with CR, PR, or stable disease (SD) according to standard criteria (RECIST v1.1).

    Time frame: Approximately 35 months

  6. ORR in Participants with CNS Metastases (ORR-CNS)

    Defined as ORR.

    Time frame: Approximately 35 months

  7. DOR in Participants with CNS Metastases (DOR-CNS)

    Defined as DOR.

    Time frame: Approximately 35 months

  8. CBR in Participants with CNS Metastases (CBR-CNS)

    Defined as CBR.

    Time frame: Approximately 35 months

  9. Changes from Baseline in Symptoms Burden in Participants With Brain Tumors

    Measured by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Brain Neoplasm module (EORTC QLQ-BN20).

    Time frame: Approximately 35 months

  10. Changes from Baseline in Function and Health-related Quality of Life (HRQoL)

    Measured by the EORTC QLQ-Core 30 (C30).

    Time frame: Approximately 35 months

  11. Incidence of Adverse Events (AEs)

    Time frame: Approximately 35 months

  12. Severity of AEs

    Severity Determined According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5.0).

    Time frame: Approximately 35 months

  13. Change from Baseline in Echocardiogram (ECHO)/Multiple-gated Acquisition (MUGA)

    Time frame: Approximately 35 months

  14. Change from Baseline in the Columbia-suicide Severity Rating Scale (C-SSRS)

    Time frame: Approximately 35 months

  15. Number of Participants Reporting Presence, Frequency of Occurrence, Severity, and/or Degree of Interference With Daily Activities of Symptomatic Treatment Toxicities as Assessed Through Use of the Patient-reported Outcome (PRO)-CTCAE

    Activities can include PPE, Mouth/Throat Sores, Nausea, Vomiting, Diarrhea, Headache, Rash, Abdominal Pain, Decreased Appetite, and Fatigue.

    Time frame: Approximately 35 months

  16. Proportion of Participants Reporting Each Response Option at Each Assessment Timepoint by Treatment Arm for Treatment Side-effect Bother Single-item Functional Assessment of Cancer Therapy (FACT-GP5)

    Time frame: Approximately 35 months

  17. Change from Baseline/Worsening in Symptomatic Treatment Toxicities as Assessed Through Use of the PRO-CTCAE

    Time frame: Approximately 35 months

  18. Change from Baseline/Worsening in Symptomatic Treatment Side-effect Bother FACT-GP5

    Time frame: Approximately 35 months

  19. Health Utility Scores of the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L)

    Time frame: Approximately 35 months

  20. Plasma Concentration of RO7771950 and its Metabolite(s) at Specified Timepoints

    Time frame: Approximately 35 months

07

Study locations

219 of 219 sites recruiting

Showing the first 100 of 219 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.

Of 56 phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 17, 2026
StartActual
May 21, 2026
Primary completionEst.
May 1, 2029
CompletionEst.
Sep 29, 2032
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
33 sites added — first site in Ukraine
Show 33 added (13 United States, 3 France, 3 Ukraine, 2 Australia, 2 China, 2 Italy, 2 Spain, 2 United Kingdom, 1 Austria, 1 Brazil, 1 Germany, 1 Belgium)
  • Clearview Cancer Institute · Huntsville, United States
  • Banner Health MD Anderson AZ · Gilbert, United States
  • UCSF Helen Diller Family CCC · San Francisco, United States
  • Eastern Connecticut Hematology and Oncology Associates · Norwich, United States
  • Stony Brook Univ Cancer Ctr · Stony Brook, United States
  • Montefiore Einstein Cancer Center · The Bronx, United States
  • Sarah Cannon Research Institute · Nashville, United States
  • Tennessee Oncology Elliston Place Plaza · Nashville, United States
  • Texas Oncology Cancer Center · Austin, United States
  • The Center for Cancer and Blood Disorders - Fort Worth · Fort Worth, United States
  • Blacktown Hospital · Blacktown, Australia
  • Sir Charles Gairdner Hospital · Perth, Australia
  • Medizinische Universität Wien · Vienna, Austria
  • Instituto D'Or Pesquisa e Ensino · São Paulo, Brazil
  • Xinjiang Medical University Cancer Hospital · Ürümqi, China
  • Institut Universitaire de Cancer de Toulouse Oncopole · Toulouse, France
  • Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie · Hanover, Germany
  • Istituto Nazionale Tumori Irccs Fondazione g. PASCALE · Naples, Italy
  • Hospital Universitari Dexeus - Grupo Quironsalud · Barcelona, Spain
  • The Clatterbridge Cancer Centre NHS Foundation Trust · Liverpool, United Kingdom
  • Community Cancer Institute (CCI) · Clovis, United States
  • UC Davis Comprehensive Cancer Center · Sacramento, United States
  • Cancer & Hematology Centers of Western Michigan · Grand Rapids, United States
  • Institut Jules Bordet · Anderlecht, Belgium
  • Hunan Cancer Hospital · Changsha, China
  • Institut Régional du Cancer de Montpellier · Montpellier, France
  • Chu La Miletrie · Poitiers, France
  • A.O. Universitaria Policlinico Di Modena · Modena, Italy
  • Fundacion Instituto Valenciano de Oncologia (IVO) · Valencia, Spain
  • Municipal Non-profit Enterprise ?SubCarpathian Clinical Oncological Centre of Ivano-Frankivsk RC? · Ivano-Frankivsk, Ukraine
  • …and 3 more on the registry record
across 2 updates, Oct 6, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    13 sites added — first site in Ukraine
    Show 13 added (3 United States, 3 Ukraine, 2 France, 1 Belgium, 1 China, 1 Italy, 1 Spain, 1 United Kingdom)
    • Community Cancer Institute (CCI) · Clovis, United States
    • UC Davis Comprehensive Cancer Center · Sacramento, United States
    • Cancer & Hematology Centers of Western Michigan · Grand Rapids, United States
    • Institut Jules Bordet · Anderlecht, Belgium
    • Hunan Cancer Hospital · Changsha, China
    • Institut Régional du Cancer de Montpellier · Montpellier, France
    • Chu La Miletrie · Poitiers, France
    • A.O. Universitaria Policlinico Di Modena · Modena, Italy
    • Fundacion Instituto Valenciano de Oncologia (IVO) · Valencia, Spain
    • Municipal Non-profit Enterprise ?SubCarpathian Clinical Oncological Centre of Ivano-Frankivsk RC? · Ivano-Frankivsk, Ukraine
    • Medical Centre of PE First Private Clinic · Kyiv, Ukraine
    • CNCE of Lviv Regional Council Lviv Oncological Regional Therapeutical and Diagnostic Centre · Lviv, Ukraine
    • Guy's Hospital - Cancer Centre · London, United Kingdom
    + 1 other change: verification date
  2. Oct 6, 2026
    20 sites added
    Show 20 added (10 United States, 2 Australia, 1 Austria, 1 Brazil, 1 China, 1 France, 1 Germany, 1 Italy, 1 Spain, 1 United Kingdom)
    • Clearview Cancer Institute · Huntsville, United States
    • Banner Health MD Anderson AZ · Gilbert, United States
    • UCSF Helen Diller Family CCC · San Francisco, United States
    • Eastern Connecticut Hematology and Oncology Associates · Norwich, United States
    • Stony Brook Univ Cancer Ctr · Stony Brook, United States
    • Montefiore Einstein Cancer Center · The Bronx, United States
    • Sarah Cannon Research Institute · Nashville, United States
    • Tennessee Oncology Elliston Place Plaza · Nashville, United States
    • Texas Oncology Cancer Center · Austin, United States
    • The Center for Cancer and Blood Disorders - Fort Worth · Fort Worth, United States
    • Blacktown Hospital · Blacktown, Australia
    • Sir Charles Gairdner Hospital · Perth, Australia
    • Medizinische Universität Wien · Vienna, Austria
    • Instituto D'Or Pesquisa e Ensino · São Paulo, Brazil
    • Xinjiang Medical University Cancer Hospital · Ürümqi, China
    • Institut Universitaire de Cancer de Toulouse Oncopole · Toulouse, France
    • Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie · Hanover, Germany
    • Istituto Nazionale Tumori Irccs Fondazione g. PASCALE · Naples, Italy
    • Hospital Universitari Dexeus - Grupo Quironsalud · Barcelona, Spain
    • The Clatterbridge Cancer Centre NHS Foundation Trust · Liverpool, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07413939
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
May 21, 2026
Primary completion
May 1, 2029 (estimated)
Completion
Sep 29, 2032 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number: WO46069 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bizrolertinib

Start the discussion